Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HARMONY: Ranolazine and Dronedarone in Paroxysmal Atrial Fibrillation
NCT01522651Phase 2Completed
- Sponsor
- Gilead Sciences
- Start
- Jan 2012
- Primary completion
- Mar 2014
- Modality
- Small Molecules
- Countries
- 7
01
Overview
Phase 2, randomised, double-blind trial of ranolazine in Atrial fibrillation (AFib) (5 arms), sponsored by Gilead Sciences. Primary endpoints: Atrial Fibrillation Burden at 12 weeks and Change from Baseline in Atrial Fibrillation Burden at 12 weeks. Started Jan 2012; status: completed.
02
Drugs
ranolazine
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on NCT01522651.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01522651.